Pharmacotherapy for obsessive-compulsive disorder

Journal of Clinical Psychology
Darin D DoughertyM A Jenike

Abstract

Pharmacotherapeutic options for obsessive-compulsive disorder (OCD) have expanded over the past half-century since medications were first found to be effective for the treatment of OCD. Currently, the serotonin reuptake inhibitors (SRIs) represent the first-line pharmacotherapy for OCD. High dosages and long trials of the SRIs are needed for adequate treatment of OCD. The use of SRIs for the treatment of OCD is reviewed, then other pharmacotherapeutic treatment options, including SRI augmentation and alternative monotherapies, are discussed. The preponderance of data demonstrates that SRI augmentation with neuroleptics is efficacious for treatment-refractory OCD. There is substantially less evidence supporting other alternative strategies. Finally, neurosurgical and device-based approaches for treatment-refractory OCD are reviewed.

References

Nov 11, 1998·Depression and Anxiety·C Cartwright, E Hollander
Mar 29, 2003·Acta Psychiatrica Scandinavica·Susanne Bejerot
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lefteris LykourasAndreas Rabavilas
Jul 15, 2003·Neurosurgery Clinics of North America·Benjamin D GreenbergSteven A Rasmussen
Jul 15, 2003·Neurosurgery Clinics of North America·G Rees Cosgrove, Scott L Rauch

❮ Previous
Next ❯

Citations

Nov 11, 2006·Current Psychiatry Reports·Peter Giacobbe, Sidney H Kennedy
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Christopher PittengerVladimir Coric
Sep 18, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Benjamin D GreenbergSuzanne N Haber
Nov 26, 2010·Cognitive Behaviour Therapy·Lisa D VaccaroBethany M Wootton
May 8, 2013·Depression and Anxiety·Meredith E ColesBarry D Weiss
Feb 14, 2015·Human Psychopharmacology·Daniele SerataAntonio Del Casale
Oct 11, 2005·Psychiatry Research·Swen HesseKatarina Stengler-Wenzke
Feb 1, 2015·The International Journal of Neuropsychopharmacology·Darin D DoughertyNancy J Keuthen
Mar 15, 2008·The International Journal of Neuropsychopharmacology·Shlomit Flaisher-GrinbergDaphna Joel
Jul 26, 2006·Ethical Human Psychology and Psychiatry·Grace E Jackson
Jan 8, 2019·Harvard Review of Psychiatry·Christoforos Iraklis Giakoumatos, David Osser
Nov 23, 2007·Journal of Psychiatric Practice·Thröstur BjörgvinssonSusan Heffelfinger
Jun 4, 2008·Journal of Psychiatric Practice·Thröstur BjörgvinssonMelinda A Stanley
Sep 18, 2013·Journal of Psychiatric Practice·Thröstur BjörgvinssonMelinda A Stanley
Jan 22, 2008·Journal of Clinical Psychopharmacology·Geum Sook ShimJun Soo Kwon
Jul 14, 2009·Journal of Clinical Psychopharmacology·Giuliana SalomoniLaura Bellodi
May 17, 2017·Proceedings of the National Academy of Sciences of the United States of America·Isaac D ZikeJeremy Veenstra-VanderWeele

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Gerard J MarekLawrence H Price
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Sîan M J HemmingsDan J Stein
Depression and Anxiety
A W Goddard, D S Charney
© 2021 Meta ULC. All rights reserved